RxDoctor Payments DataLook up a doctor →

Stephen Montaquila

Optometrist · Warwick, RINPI 1326003674

Payments from drug & device makers

$1,944,811in general payments, 2019–2025

Across 1,817 payments — averaging $1070.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$986K
  • Johnson & Johnson Vision Care, Inc.$486K
  • Oyster Point Pharma, Inc.$152K
  • AbbVie$87K
  • Bausch Health US, LLC$81K
  • Sight Sciences, Inc.$69K
  • plus $84K from 13 others
$61,834in research payments, 2019–2025

Across 6 payments — averaging $10,306 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$34K
  • Coopervision Inc.$28K

What the payments were for

  • Consulting fees$27,66154%
  • Speaking & faculty fees$10,27520%
  • Travel & lodging$6,10712%
  • Food & beverage$7,03714%
  • Gifts$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,944,811 in reported general payments places this provider in the 95th percentile of 226 optometrist providers in Rhode Island.

See all optometrist providers in Rhode Island

Medicare billing

Part B allowed, 2024
$60,992
Medicare patients
318
Services billed
2,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine26$35,174
LumiganBimatoprost23$10,243
Bromfenac Sodium14$1,592
Tobramycin-DexamethasoneTobramycin/Dexamethasone19$1,480
Fluorometholone11$1,227
Latanoprost69$1,144
Timolol Maleate44$781
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat34$765
Doxycycline Monohydrate13$348
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha21$254
Brimonidine Tartrate12$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$86,911$45,41749 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 optometrist providers in Rhode Island.

Other optometrist in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →